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The intestinal microflora is not only involved in the digestion of nutrients, but also in local immunity, forming a barrier against
pathogenic microorganisms. The derangement of the gut microflora may lead to microbial translocation, defined as the passage of
viable microorganisms or bacterial products (i.e., LPS, lipopeptides) from the intestinal lumen to the mesenteric lymph nodes
and other extraintestinal sites. The most recent evidence suggests that microbial translocation (MT) may occur not only in
cirrhosis, but also in the early stage of several liver diseases, including alcoholic hepatopathy and nonalcoholic fatty liver disease.
Diﬀerent mechanisms, such as small intestinal bacterial overgrowth, increased permeability of intestinal mucosa, and impaired
immunity, may favor MT. Furthermore, MT has been implicated in the pathogenesis of the complications of cirrhosis, which are a
significant cause of morbidity and mortality in cirrhotic subjects. Therapeutic strategies aiming at modulating the gut microflora
and reducing MT have focused on antibiotic-based options, such as selective intestinal decontamination, and nonantibiotic-
based options, such as prokinetics and probiotics. In particular, probiotics may represent an attractive strategy, even though the
promising results of experimental models and limited clinical studies need to be confirmed in larger randomized trials.
1. Introduction
The intestinal microflora is a complex ecosystem, consisting
of more than 500 microbial species, that are involved in
the digestion of nutrients and the production of vitamins
and short-chain fatty acids; furthermore, the gut microflora
plays a role in local immunity, forming a barrier against
pathogens, together with the intestinal mucosa [1]. The
derangement of the gut microflora and increased microbial
translocation (MT) have been widely described in advanced
liver disease and associated with the pathogenesis of the
complications of cirrhosis [2]; moreover, recent lines of
evidence suggest the intestinal microflora to be directly
implicated in the induction and progression of liver damage
in several chronic liver diseases, including alcoholic and non-
alcoholic steatohepatitis, two common causes of cirrhosis
[3–5].
Here, we review current concepts regarding the patho-
genesis of MT, its role in liver diseases and the potentialities
of therapeutic strategies based on the modulation of intesti-
nal flora (i.e. probiotics).
2. Microbial Translocation in Cirrhosis
Microbial translocation (MT) is defined as the migration of
viable microorganisms or bacterial endotoxins (i.e., bacte-
rial lipopolysaccharide (LPS), peptidoglycan, and lipopep-
tides) from the intestinal lumen to the mesenteric lymph
nodes (MLN) and other extraintestinal sites [6, 7]. Gram-
negative members of the Enterobacteraceae family (such
as Escherichia coli and Klebsiella spp.), enterococci, and
other streptococci species are the most eﬀective at bacterial
translocation to MLN, across even histologically normal
intestinal mucosa [8, 9]. On the contrary, anaerobic species
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only rarely translocate and they have been reported to limit
the growth of aerobic species with higher translocation
potentialities [10].
Increased MT has been described both in experimental
animal models of cirrhosis and in cirrhotic patients. In
animal studies, the prevalence of MT, defined as a positive
bacteriological culture from surgically removed MLN, was
around 50% in cirrhotic rats with ascites [11] and up to 80%
in cirrhotic rats with spontaneous bacterial peritonitis (SBP)
[12–14]. In humans, few studies are available, because of the
diﬃculty in detecting MT to MLN and the lack of widely
applicable noninvasive markers of MT. However, MT seems
to occur more frequently in Child C cirrhotic patients (about
30% of positive MLN cultures), in comparison with Child B
and A cirrhotic patients (8% and 3%, resp.) [15]; in addition,
levels of tumour necrosis factor (TNF)-α were found to be
higher in MLN of cirrhotic patients than in controls and to
correlate with Child-Pugh score and to the risk of developing
bacterial infections during the first month after transplant
[16].
Detection of bacterial deoxyribonucleic acid (bactDNA)
in blood and ascites using the polymerase chain reaction
(PCR) has been proposed as a sensitive surrogate marker
of MT [17–19]. Such et al. [17] detected the presence of
bactDNA (mainly E. coli) simultaneously in blood and ascites
in as many as 32% of patients with advanced cirrhosis and
sterile nonneutrocytic ascitic fluid. Of importance, bactDNA
sequence similarity in blood and ascites suggested a shared
origin, from a common MT event. Unfortunately, there was
no correlation between the severity of liver disease and the
detection of bactDNA in body fluids, so that the clinical
impact of molecular methods to detect MT remains to be
established.
2.1. Pathogenesis of Microbial Translocation. Cirrhosis may
lead to MT via diﬀerent mechanisms, including small
intestinal bacterial overgrowth (SIBO), disturbance of lumi-
nal factors, increased permeability of intestinal mucosa,
and impaired immunity. These factors are summarized in
Figure 1.
SIBO. SIBO has been shown to frequently occur in the
setting of chronic liver diseases and to be related to the
degree of hepatic dysfunction [20]. The diagnosis of SIBO is
based on the use of glucose breath hydrogen tests [21, 22]
or quantitative culture of jejunal aspirates [20, 23]. The
limited sensitivity of breath tests [24] may explain the lower
prevalence rates of SIBO (about 30–38% versus 48–73%)
found when using breath tests [21, 22] rather than jejunal
colony counts [23, 24] to detect bacterial overgrowth.
A number of explanations may account for SIBO, includ-
ing hypochlorhydrosis, malnutrition, and intestinal hypo-
dysmotility [24–26]. The pathogenesis of small intestinal
hypomotility in cirrhosis is multifactorial, as a result of
increased adrenergic activity, enhanced nitric oxide (NO)
production, and structural intestinal damage, due to oxida-
tive stress and portal hypertension [20, 27]. Of note, SIBO
itself may further compromise intestinal motility [28, 29],
thus creating a vicious cycle that amplifies bacterial over-
growth. In animals, the administration of prokinetics, like
cisapride [23, 30], and β-adrenergic blockers, like propanolol
[31], has been reported to reduce SIBO and MT; in clinical
practice, a six-month trial with cisapride showed decreased
orocaecal transit time and SIBO elimination in 80% of
patients with SIBO at baseline [23, 32]. Unfortunately,
cisapride has been withdrawn from use in some countries
because of potential for cardiac arrhythmia.
Disturbance of Luminal Factors. Several luminal factors,
such as bile acids, secretory immunoglobulin A, mucins,
defensins, lysozyme, and phospholipase A2, physiologically
contribute to the intestinal barrier against MT. Bile acids
inhibit bacterial overgrowth, especially of anaerobic species;
moreover, the absence of bile in the intestine has been shown
to promote MT [33]. In cirrhosis, the reduced secretion
of bile acids may favor SIBO and MT. Of interest, oral
administration of conjugated bile acids, cholylsarcosine, and
cholylglycine has been reported to reduce intestinal bacterial
content and to decrease the rate ofMT in ascitic cirrhotic rats
[34]. Further studies should evaluate the potential benefits of
bile acids in humans.
Impaired Immunity. Cirrhosis is accompanied by several
abnormalities of both systemic and local immune system.
The reticulo-endothelial system (RES), whose activities are
mainly located in the liver (Kupﬀer cells), is the main defense
against bacteremia; in cirrhosis, phagocytic activity of Kupf-
fer cells may be impaired and the presence of portosystemic
shunts bypassing the liver (thereby escaping the action of
the RES) may explain the failure to clear not only portal
or systemic bacteria, but also endotoxins and cytokines
[35]. In cirrhotic subjects, serum complement levels have
been reported to be low [36, 37] and to independently
predict the risk of infections and mortality [37]. Cirrhosis
is also accompanied by a decrease in bactericidal activity by
monocytes and neutrophils [38, 39]. An increased number of
intraepithelial lymphocytes withmarkedly impaired prolifer-
ative activity and capacity to produce interferon-γ have been
reported in a murine model of cirrhosis and correlated with
increased MT [40]. Considering the crucial role of intestinal
immune cells in regulating the interplay between the host
and gut flora, it can be assumed that the derangement of local
immunity may allow translocated bacteria to escape from
MLN and to reach systemic blood and other extraintestinal
sites.
Increased Permeability. Structural and functional changes in
intestinal mucosa may increase its permeability, contribut-
ing to the development of MT. Structural abnormalities,
whose most important determinant appears to be portal
hypertension, include vascular congestion, thickened mus-
cularis mucosa, fibromuscular proliferation, and a reduced
villus/crypt ratio [41]. In addition, ultrastructural abnormal-
ities in the epithelial layer of small intestine specimens of
cirrhotic subjects have been described [42]. In experimental
cirrhosis, oxidative damage of the intestinal mucosa has
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Figure 1: Mechanisms of microbial translocation in chronic liver diseases. LPS: lipopolysaccharide; NO: nitric oxide; GALT: gut-associated
lymphatic tissue; TNF-α; tumour necrosis factor.
been shown to cause lipid peroxidation of the brush border
membranes and abnormal intestinal transport [43, 44].
Most functional studies, usually dual sugar absorption tests,
have found increased intestinal permeability in patients
with advanced liver disease [45–48]. Increased permeability
is likely to occur via a paracellular route. In humans,
morphologically intact tight junctions at the apical pole of
enterocytes have been reported in a cohort of clinically stable
cirrhotic patients with no prior history of infection with
gut-derived bacteria [42], but it remains to be established
whether tight junctions are intact in cirrhotic patients
with a history of infection with enteric bacteria. Notably,
dilatation of the intercellular space below tight junctions has
been documented in patients with cirrhosis [32] and, more
importantly, NO, whose role in cirrhosis is discussed below,
has been shown to reversibly dilate tight junctions, to destroy
the cytoskeleton, and to inhibit the formation of adenosine
triphosphate in cultured intestinal epithelial cells [49].
2.2. Not Only Microbes: Endotoxins and Cytokines in Cirrhosis.
As previously stated, MT does not only refer to the passage
of viable bacteria, but also of microbial products, across
the gut mucosa, thus causing the production of proinflam-
matory cytokines and vasoactive mediators. Patients with
cirrhosis have been reported to have increased circulating
levels of endotoxin (LPS), a cell wall component of Gram-
negative bacteria [50, 51]; MT, as well as reduced hepatic
clearance, may be responsible for the spill-over of intestinal
endotoxin into the systemic circulation. In fact, endotoxemia
is significantly more frequent in cirrhotic rats with MT
than in cirrhotic animals without MT [52]. Furthermore,
MT itself has been reported to make the gut a “cytokine-
releasing organ”, even in the absence of portal or systemic
bacteremia [53, 54]. Endotoxin-primed macrophages release
high levels of TNF-α in experimental models of liver damage
[55–57]. In rats, TNF-α levels in MLN have been shown to
be higher in presence of MT and to correlate with TNF-
α plasma levels [58]; in humans, as previously reported,
elevated levels of TNF-α in MLN of cirrhotic subjects have
been found and significantly correlated with those detected
in the blood [16]. The overproduction of proinflammatory
cytokines has been associated with elevated plasma levels
of LPS-binding protein (LBP), which is synthesized in the
liver in response to endotoxin and promotes the binding of
endotoxin to the CD14/Toll-like receptor 4 (TLR4) receptor
complex [59]. Based on these observations, endotoxemia has
been proposed as a major cause of the proinflammatory state
in cirrhotic subjects [60–62]. However, other studies have
failed to show a significant association between circulating
endotoxin and proinflammatory cytokines levels [63–65].
Moreover, contrary to previous assumptions, Riordan et al.
suggested to focus more on Gram-positive bacteria rather
than Gram-negative ones: in fact, the authors described the
upregulation of TLR2, responsible for signaling in response
to Gram-positive microbial stimuli, but not of TLR4, on
peripheral blood mononuclear cells (PBMCs) of cirrhotic
subjects; in addition, TLR2 on PBMCs correlated with
circulating levels of both TNF-a and soluble TNF receptors,
while TLR4 did not [66].
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3. Taking a Step Back: Role of MT in the
Induction and Progression of Liver Damage
in Chronic Viral Hepatitis, Alcohol-Induced
Hepatopathy, and NAFLD
So far, we have focused on MT in the context of cirrhosis
pathophysiology, but it must be taken into account that MT
may work as a “trigger” in the induction and progression of
various kinds of hepatic injury (i.e., inflammation, steatosis,
fibrosis, and possibly cirrhosis) in several liver diseases,
such as alcoholic, metabolic, and viral hepatitis. In fact,
the derangement of the gut microflora and MT has been
described even at the early stages of liver disease.
Alcoholic Hepatitis. Even if alcohol metabolism predomi-
nantly occurs in the liver, it is known that colonic bacteria are
able to produce large amounts of acetaldehyde from ethanol
[67–69]; acetaldehyde is responsible, in turn, of increased
intestinal permeability and increased translocation of LPS
to the portal vein and on to the liver [70]. In fact, plasma
endotoxin levels have been shown to be higher than healthy
controls not only in subjects with alcoholic cirrhosis, but also
in patients with mild forms of alcoholic hepatitis [71, 72].
In the liver, the LPS/TLR4 pathway has been demonstrated
to promote fibrogenesis, by sensitizing stellate cells to
transforming growth factor-β (TGF-β)-induced signals and
promoting TGF-β release by Kupﬀer cells [73]. Experiments
in rats [74] and clinical studies in humans [75–77] have
demonstrated both quantitative and qualitative changes in
the gut microflora of alcoholic subjects, in comparison
with controls. In addition, ethanol-mediated oxidative stress
appears to be an important mechanism that leads to gut
leakiness and increased MT [78–81]. In particular, the over-
production of NO and its metabolite peroxynitrite (ONOO-)
has been associated with the disruption of the intestinal
epithelial layer. NO is synthesized from L-arginine by NOS.
Three isoforms of NOS have been identified: neuronal
(n)NOS, endothelial (e)NOS, and inducible (i)NOS. While
nNOS and eNOS are considered protective for the intestinal
mucosa, iNOS may be induced by bacterial products and
cytokines and it is believed to significantly contribute to local
inflammation and hyperpermeability [82], as confirmed by
the observation of reduced alcohol-induced gut leakiness
when administering iNOS inhibitors [78]. Furthermore,
alcohol has been reported to dysregulate immune responses,
suppressing natural killer cell activity, antibody-dependent
cell-mediated cytotoxicity, and T-cell-dependent antibody
responses, thus globally increasing the host susceptibility to
pathogenic bacteria of the gut [83, 84].
Viral Hepatitis. Several studies reported elevated LPS levels
in the context of chronic viral hepatitis by hepatitis C virus
(HCV) and hepatitis B virus (HBV) [85, 86]. In a recent
work, Sandler et al. [86] have retrospectively investigated
whether the extent and progression of liver disease in patients
with chronic HBV or HCV infection were associated with
MT and the subsequent local and systemic inflammation.
HCV- and HBV-infected individuals had higher plasma
levels of LPS, soluble (s)CD14 (produced upon LPS acti-
vation of monocytes), and interleukin-6, in comparison
with controls. Levels of sCD14 correlated with markers of
hepatic inflammation and fibrosis and were significantly
higher in subjects with severe fibrosis at presentation, in
comparison with those having minimal fibrosis (P = 0.01).
Importantly, sCD14 was significantly higher in progressors
than nonprogressors (P = 0.003); moreover, an increase in
sCD14 of 1.0×106 pg/ml was associated with an odds ratio of
disease progression of 3.7 (P = 0.007), with no changes after
adjustment for other prognostic factors. Of note, elevated
sCD14 levels, but not LPS itself, predicted clinical outcome.
Recent lines evidence coming from studies on HIV-
HCV coinfected cohorts have reported a similar correlation
between sCD14 and the severity of liver disease [87, 88].
In addition, Marchetti et al. [87] have recently investigated
whether baseline MT (as assessed by measuring LPS levels)
or host response to MT (sCD14) could be predictive of early
virological response (EVR: HCV-RNA <50 IU/mL at week 12
of therapy or≥2 log10 reduction from baseline after 12 weeks
of therapy) and sustained virological response (SVR: HCV-
RNA <50 IU/mL 24 weeks after end of therapy) to HCV
treatment. In the univariate model, the authors found that
lower sCD14 levels were predictive of both EVR and SVR,
while LPS were not; however, sCD14 lost its independent
predictive value in the multivariable model, thus limiting the
possibility to use it in clinical practice as measure to a priori
include/exclude patients from treatment.
Metabolic Hepatitis. Nonalcoholic fatty liver disease
(NAFLD) is the most common cause of liver disease in
industrialized countries. It usually develops in the setting of
obesity and insulin resistance and comprises a continuum
of disease ranging from simple steatosis to steatohepatitis
(NASH) to cirrhosis. Obesity has been associated with
changes in the gut microflora [4] and increased intestinal
permeability [89–91]. In subjects with NAFLD, the
prevalence of SIBO has also described as higher than
controls [91, 92]. A high-fat diet has been reported not
only to increase intestinal translocation of endotoxin in
mice (the so-called metabolic endotoxemia), but also to
reduce enteric Bifidobacteria [93, 94], a group of bacteria
that have been shown to lower intestinal LPS levels and
to improve mucosal barrier function [95]. Furthermore,
mice chronically receiving a continuous low rate of LPS, as
well as high-fat diet-fed mice, developed insulin resistance,
had high circulating levels of proinflammatory cytokines
and increased liver triglyceride content. These eﬀects were
completely blunted in CD14mutant mice [94]. Other studies
have shown that even the early stages of fructose-induced
NAFLD (e.g., steatosis) are associated with increased
intestinal translocation of endotoxin and expression of
TNF-α in the liver, whereas TNF-α expression and steatosis
were markedly lower in the liver of fructose-fed mice treated
with antibiotics or TLR-4-mutant mice [96, 97]. In humans
with NAFLD, TNF-α expression was reported to be increased
too [92, 98]. These data globally support the idea that the
LPS/CD14 system has a pivotal role in the induction of the
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low tone inflammatory status of metabolic disease, setting
the threshold of insulin sensitivity and the onset of diabetes
and obesity.
4. Taking a Step Forward: Role of MT
in the Pathogenesis of the Complications
of Cirrhosis
The gut microflora has been shown to contribute to the
pathogenesis of the complications of cirrhosis, including
the development of spontaneous bacterial infections and
worsening of the hyperdynamic circulatory state (HCS),
a hemodynamic perturbation that may lead to ascites,
esophageal variceal growth and hepatorenal syndrome.
Spontaneous bacterial infections (i.e., SBP, empyema,
and bacteremia) have an incidence rate of 15%–47% in
cirrhotic subjects [99–103] and are mainly caused by Gram-
negative bacteria, even though the incidence of infections
from Gram-positive cocci has increased in recent series, as
a consequence of the use of chronic antibiotic prophylaxis
[104–106] and more frequent therapeutic invasive proce-
dures [102]. Mortality is significantly higher in cirrhotic
patients developing an infection [101, 103]. SBP, an infection
of ascitic fluid typically with a single bacterial species, in the
absence of any other primary intra-abdominal source, has
been shown to be present in up to 23% of cirrhotic patients
with ascites undergoing paracentesis [107]. An increased
prevalence of SBP has been described in patients with SIBO
[108]; conversely, subjects with SBP have a higher prevalence
of SIBO than those without SBP [109]. Animal studies have
established a causal link between MT and SBP [14]; in
humans, this relationship is supported by the observation
that selective intestinal decontamination (SID) by the use
of oral nonabsorbable antibiotics is eﬀective in decreasing
the incidence of spontaneous bacterial infections in cirrhotic
subjects [110–113].
MT has been postulated as an important mechanism in
the development of the cirrhotic HCS, which is characterized
by low vascular resistance, low mean arterial pressure,
and by increased heart rate, cardiac output, and regional
blood flow. The HCS is mainly due to splanchnic and
systemic vasodilatation, which result in “underfilling” of the
arterial system and subsequent activation of compensatory
mechanisms (i.e., renin-angiotensin aldosterone, sympa-
thetic nervous system, and antidiuretic hormone), which are
responsible for increased plasma volume and cardiac output.
The HCS contributes to portal hypertension andmany of the
complications of cirrhosis [2, 114]. NO appears to be the key
vasodilator responsible for the haemodynamic abnormalities
of cirrhosis [115]. It has been reported that gut-derived
endotoxins and the resultant increase in inflammatory
cytokines are able to induce the expression of iNOS in vessel
walls, causing NO overproduction, vasodilatation, and HCS
[116]. Endotoxemia has been shown to correlate with serum
NO-metabolite levels [117, 118]; moreover, HCS appears to
be more marked in patients with cirrhosis and ascites having
high levels of LBP [59]. The role of cytokines, specifically
TNF-a, in the development of the HCS is evidenced by
studies showing that TNF-a inhibitors ameliorate HCS in
cirrhotic rats [119]. The importance of the gut microflora
in inducing the production of vasoactive mediators has
suggested to use SID as a strategy to decrease bacterial
overgrowth and MT, in attempts to ameliorate the HCS.
Patients treated with a 4-week course of oral norfloxacin
demonstrated improvement in biologic and hemodynamic
end points, with trends toward reduction in cardiac output,
improvements in mean arterial blood pressure and reduced
MT [59, 120].
A growing amount of data suggests that bacterial infec-
tions may work as an important trigger for variceal bleeding
in patients with cirrhosis [121, 122], possibly as a conse-
quence of enhanced activation of hepatic stellate cells, which
may increase intrahepatic vascular resistance and portal
hypertension and precipitate the coagulopathy that results
from prostacyclin-related inhibition of platelet aggregation,
consumption of clotting factors by the extrinsic coagu-
lation pathway and reduction of endogenous heparinoids
[122–124]. Conversely, variceal haemorrhage predisposes
to bacterial infections with gut-derived microflora, thus
creating a vicious cycle between gastrointestinal bleeding and
infections, which significantly increases the mortality rates in
this group of patients [125–127].
MT may also participate in the pathogenesis of hepatic
encephalopathy (HE). HE is associated with the presence
of portal and systemic shunts and the failure of the liver
to clear ammonia and other toxic products derived from
the gut [128, 129]. Ammonia is produced in both the small
bowel (from the eﬀects of glutaminase on glutamine) and
large intestine (from urease activity of the colonic flora).
Colonic bacteria may also produce gamma-amino-butyric
acid (GABA) and benzodiazepine (BZD)-like substances
[130, 131], which have been implicated in the development
of HE [132, 133]. The role of the gut microflora in the
pathogenesis of HE is supported by the observation that
total colectomy is eﬀective in reducing baseline and protein-
induced ammonia production [134], reversing cases of HE
which had not been responsive to medical treatment [135].
Nevertheless, HE may recur, probably as a consequence of
the colonization of the small bowel [136].
5. Searching for Effective Therapeutic
Options: Selective Intestinal
Decontamination and Probiotics
Modulation of the intestinal microflora through the use of
selective intestinal decontamination (SID) and probiotics has
been proposed as an emerging therapeutic strategy in the
management of chronic liver diseases.
SID. Long-term use of norfloxacin, a poorly absorbed
quinolone, has been reported to markedly reduce the count
of intestinal aerobic Gram-negative bacilli, but not Gram-
positive cocci or anaerobic bacteria [112]. In cirrhotic
animals, some studies have shown that the use of oral
norfloxacin or trimethoprim/sulfamethoxazole was associ-
ated with a decrease in BT [137, 138], while other studies
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have not [139]. In the clinical setting, a double blind,
placebo-controlled trial evaluating the long-term eﬃcacy of
norfloxacin in cirrhotic patients who had survived a previous
episode of SBP, found a significant reduction of the risk of
SBP recurrence in the treated group (20% versus 68%) at
one year of followup [112]. In cirrhotic patients with low
ascitic fluid protein concentrations, long-term prophylactic
treatment with norfloxacin was eﬀective even in the pre-
vention of the first episode of SBP, but a major concern
of long-term antibiotic prophylaxis is the development of
quinolone-resistant infections [140]. Of interest, primary
prophylaxis with norfloxacin has been associated with
higher rates of trimethoprim–sulfamethoxazole resistance
and increased incidence of infections with Gram-positive
bacteria, including severe hospital-acquired staphylococcal
infections [102, 106, 141]. On the basis of these observations,
it is crucial to define non-antibiotic strategies to reduce MT
and prevent infections.
Probiotics. Probiotics, commonly lactose-fermenting Lacto-
bacilli and Bifidobacteria, have been reported to stabilize
mucosal barrier function and modulate the gut microflora,
limiting the growth of pathogenic bacteria, by acidifying
the gut lumen, competing for nutrients, and producing
antimicrobial substances [95, 142].
In vitro, the probiotic Lactobacillus casei GG has been
shown to inhibit the translocation of E. coli in a dose-
dependent manner [143]; however, in vivo lines of evi-
dence are controversial. Some studies performed in cir-
rhotic rats have failed to find significant diﬀerences in MT
rates between cirrhotic animals receiving Lactobacilli and
untreated controls [144, 145]. On the other hand, Forsyth et
al. described reduced gut leakiness and less severe alcoholic
steatohepatitis in alcohol plus Lactobacillus GG-fed rats, in
comparison with alcohol-fed rats [146]. A combination of
Lactobacillus johnsonii LA1 and antioxidants was eﬀective
in reducing MT, oxidative damage, and endotoxemia in
rats with CCl4-induced cirrhosis; unfortunately, the authors
did not include a group receiving Lactobacillus johnsonii
LA1 alone [147]. In experimental models of NAFLD, it has
been reported that mice treated with VSL#3 (containing
Streptococcus thermophilus, B. breve, B. longum, B. infantis,
L. acidophilus, L. plantarum, L. casei, and L. bulgaricus) had
lower liver inflammation, serum alanine aminotransferase
(ALT), and hepatic total fatty acid content in comparison
with controls [148]. Similarly, a recent work of Xu et al.
has shown reduced fat accumulation in the liver of high-
fat diet-fed rats receiving Bifidobacterium longum and in
those receiving Lactobacillus acidophilus, in comparison with
high-fat diet-fed controls. Of interest, intestinal permeability
was not aﬀected by probiotics; furthermore, Bifidobacterium
longum was more eﬀective than Lactobacillus acidophilus in
attenuating liver fat accumulation [149]. In high-fat diet-
fed mice, VSL#3 administration has been associated with
decreased hepatic steatosis and insulin resistance, as well
as reduced expression of lipid peroxidation markers, TNF-
α, iNOS, cyclooxygenase 2, and matrix metalloproteinases
(MMPs) [150, 151]; in another study, the use of VSL#3
ameliorated hepatic fibrosis, by decreasing expression of
procollagen and MMPs, but not steatosis or inflammation
[152].
In humans, VSL#3 administration has been reported to
reduce oxidative stress in patients with NAFLD and alcoholic
liver cirrhosis, but not chronic hepatitis C [153]. Cirrhotic
subjects receiving Escherichia coli Nissle for 42 days showed
a trend toward lower endotoxin levels and improvement
in Child-Pugh score [154]; similar results were obtained
by Liu et al. when administering a symbiotic compound
(a mixture of lactic acid bacteria and fermentable fiber),
Synbiotic 2000, to cirrhotic patients [155]. A significant
reduction in Child-Pugh class occurred in 47% of patients
receiving Synbiotic 2000 for 30 days, whereas this only
occurred in 29% of patients randomized to fiber alone
and 8% of patients on placebo. Of importance, stool
analysis demonstrated the reduction of Gram-negative fecal
flora; furthermore, Synbiotic 2000 was associated with a
significant improvement of minimal hepatic encephalopathy
(MHE) and decreased endotoxemia. On the basis of these
observations, it is possible to hypothesize the beneficial role
of symbiotics in modulating the gut flora and reducing MT,
as confirmed by the lower circulating endotoxin levels found
in symbiotic-treated subjects. Opposing results were recently
reported in a study of Pereg et al., who failed to show
any beneficial eﬀect of probiotic administration in patients
with compensated liver cirrhosis [156]. In this double-
blind placebo-controlled study, 36 patients were randomly
assigned to receive probiotic capsules containing Lactobacil-
lus acidophilus, Lactobacillus bulgaricus, Bifidobacterium lactis
and Streptococcus thermophiles or placebo for 6 months.
No diﬀerences in either clinical or laboratory parameters
between the two groups were found; the small size of the
study population, the reduced number of patients having
a Child-Pugh class >A, and the longer period of treatment
may globally explain the diﬀerent conclusions of this trial in
comparison with those described above.
As refers to the use of probiotics for the prevention of
infections, it has been reported that a symbiotic regimen
including Lactobacillus plantarum and fermentable fiber was
more eﬀective than SID in reducing the incidence of bacterial
infections in liver transplant recipients [157]. Analogously, a
follow-up randomized double-blind trial in liver transplant
recipients has shown the rate of postoperative bacterial
infections to be significantly lower in subjects receiving a
mixture of lactic acid bacteria and fermentable fiber, in
comparison with fermentable fiber alone [158].
The eﬀects of the prebiotic lactitol on the intestinal flora
and plasma endotoxin levels have recently been evaluated
in patients with chronic viral hepatitis [159]. Lactitol and
lactulose are synthetic non-absorbable disaccharides, widely
used in the treatment of HE; due to the lack of a suitable
galactosidase in the upper part of the gastrointestinal
tract, they are able to reach undigested the large bowel,
where they are metabolized by colonic bacteria, generating
organic acids [160]. The resulting lower pH may inhibit
urease-producing intestinal bacteria and promote the growth
of non-urease-producing lactobacilli [161]; on the basis
of these observations, it is unsurprising the report by
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Chen et al. [159] of increased levels of beneficial bacteria,
such as Bifidobacteria and Lactobacilli, in lactitol-receiving
patients with HCV, with a consensual decline in endotox-
emia, in comparison with untreated controls.
In the setting of HE, current approaches include the
use of non-absorbable antibiotics (i.e. neomycin, paro-
momycin, metronidazole, or rifaximin) and non-absorbable
disaccharides [162]. Probiotics appear to be a promising
therapeutic option in the management of HE [155, 163–
166]. In fact, some studies have shown that probiotics
may positively modulate the gut microflora, reducing the
amount of bacterial ammonia reaching the portal vein.
The long-term oral administration of Enterococcus faecium
SF 68 was at least as eﬀective as lactulose in improving
neurocognitive tests and reducing ammonia levels in patients
with HE. Of importance, in this trial the improvement in
mental status was maintained during the washout peri-
ods in probiotic-treated subjects, but not in lactulose-
treated ones [163]. Similarly, cirrhotic patients with minimal
hepatic encephalopathy receiving Bifidobacterium longum
plus fructo-oligosaccharides for 3 months had a significant
improvement in both biochemical and neuropsychological
tests compared to controls [164].
6. Conclusions
The interaction between the gut microflora and the host may
play a crucial role in the natural history of chronic liver
diseases. In clinical practice, there is a need of surrogate
markers of MT and non-antibiotic methods, which may
positivelymodify the gut ecosystem and reduce the passage of
bacteria and bacterial products through the gut. Considering
the results coming from experimental models and limited
clinical studies, probiotics are an attractive strategy, but they
need further investigation in larger controlled clinical trials.
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